ARTHEx Biotech

Biotechnology ResearchValencian Community, Spain11-50 Employees

ARTHEx Biotech is a spin-off biotech company from the University of Valencia (Spain) focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs. 
 
ARTHEx has developed its proprietary platform that allows fast and flexible development of investigational miR-modulating oligonucleotides that are designed to enter relevant tissues in pharmacological quantities, in order to treat diseases in which microRNAs play a key role.

The first investigational product from this platform is ATX-01, an antimiR in  development for Myotonic Dystrophy Type 1 (DM1). DM1 is an orphan disease affecting more than 900,000 people worldwide (estimated prevalence 1/8,000) with no cure, nor approved treatment to date. ATX-01 is a first-in-class disease-modifying therapy that addresses the cause of DM1 with a dual and unique mechanism of action, which targets micro-RNA-23b a key factor in the disease pathogenesis.

To learn more about Arthex Biotech, please visit us at  www.arthexbiotech.com

Sign up for free to view info

Email Format Employee directory